Physician
Hematology
Dr. Nicholas J. Vogelzang, MD
|
|
Give Review
Nicholas Vogelzang works in the field of Hematology. He graduated from University of Illinois College of Medicine. He received 6 awards: "Vegas Seven", "America's Top Doctors", "America's Top Doctors for Cancer", "Desert Companion", "Fellow (FASCO)" and "Chicago Magazine: Top Doctors". Dr. Nicholas J. Vogelzang is a published doctor and has 99 publications published. The lastest was: 'Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.' He accepts Medicare.
Publications
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
- A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after doceta...
- Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
- Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
- Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of...
- P1.05A ph 1 study of 2 different schedules of the PSMA-tubulysin small-molecule drug conjugate EC1169 in pts with rec Met Cast-Resist PC (MCRPC).
- Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention.
- First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Commun...
- A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase 3 metastatic castration resistant prostate cancer trial.
- Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study.
- A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.
- Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the Uni...
- Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin.
- A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer.
- Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
- Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices.
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...
- Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
- Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort.
- Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421.
- Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
- Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma.
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
- Pooled analysis of clinical outcomes with neoadjuvant Cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.
- Management of Castrate Resistant Prostate Cancer-Recent Advances and Optimal Sequence of Treatments.
- Intermittent versus continuous androgen deprivation in prostate cancer.
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospec...
- A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castratio...
- Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
- Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology.
- Everolimus vs. Temsirolimus for Advanced Renal Cell Carcinoma: Use and Use of Resources in the US Oncology Network.
- Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status.
- Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
- Current Vaccination Strategies for Prostate Cancer.
- A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors.
- Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.
- Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients ...
- Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer.
- Use of testosterone replacement therapy in patients with prostate cancer.
- Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors.
- Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostat...
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study.
- Another step toward the cure of metastatic renal cell carcinoma?
- Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer.
- Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A sec...
- First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?
- Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patie...
- Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
- Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate.
- Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
- Long-term response in primary renal cancer to sequential antiangiogenic therapy.
- Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
- Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
- Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
- Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
- COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.
- Call for revision of College of American Pathologists-mandated requirements for retention of laboratory records and materials.
- From the guest editors: the dramatic advances in the treatment of metastatic renal cancer that have occurred over the last 3 years, with an eye toward the potential fu...
- Conclusion and future directions.
- Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
- Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
- Cancer in Nevada's adolescent and young adult population.
- Second-line chemotherapy for advanced hormone-refractory prostate cancer.
- Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
- Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia...
- The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
- Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatme...
- Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
- Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
- Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
- Classification of renal neoplasms based on molecular signatures.
- Activities and accomplishments of the cancer and leukemia group B genitourinary committee.
- Variability in mesothelioma tumor response classification.
- Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
- A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
- Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer a...
- Treatment options in metastatic renal carcinoma: an embarrassment of riches.
- Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
- Promising systemic therapy for renal cell carcinoma.
- Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
- New agents in the management of advanced mesothelioma.
- Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.
- A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
- The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
- Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
- Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
- A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
- Multimodality therapy in mesothelioma: role of chemotherapy.
- Novel agents for the treatment of advanced kidney cancer.
- Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
- Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
- Gene expression profiling of mesoblastic nephroma and Wilms tumors--comparison and clinical implications.
Schools
University Of Illinois College Of Medicine Chicago
Rush Presby St Lukes
University Of Minnesota
Trinity Christian College
Procedures Preformed
- Cancer Treatment
- Immunotherapy
- Thoracentesis
Doctors Specialties
- Cancer Research
- Hematology
- Internal Medicine
- Oncology
Accepted Insurances
Awards
- Vegas Seven
- America's Top Doctors
- America's Top Doctors for Cancer
- Desert Companion
- Fellow (FASCO)
- Chicago Magazine: Top Doctors
Education
-
University of Minnesota at Fairview -
Rush University Medical Center -
University of Illinois College of Medicine
Drug Facts
| NPI NUMBER | 1558361154 | |
| NPPES Provider LastName | VOGELZANG | |
| NPPES Provider FirstName | NICHOLAS | |
| NPPES Provider ZIPCode | 891693321 | |
| NPPES Provider State | NV | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1581.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 125.0 | |
| Percent Opioid Claims | 7.91 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1558361154 |
| Last Name Of The Provider | VOGELZANG |
| First Name Of The Provider | NICHOLAS |
| View All |
Similar Doctors
|
Dr. Reza Vaghefi Hosseini, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Warren L. Wheeler, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Majid Hajizadeh-Bashy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tanveer Akbar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Fadi Braiteh, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Edwin C. Kingsley, MD |
|
|
Dr. Altaf Dawood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jorge Solis-Valdez, MD |
|
Dr. Holavanahall S. Keshava-Prasad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Noel M. Rowan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Clark S. Jean, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Oscar B. Goodman Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiantuo Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arnold Wax, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sean Steele, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacey L. Garry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine Ruemmler-Fisch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yupo Ma, MD |
|
Dr. Heather J. Allen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erik R. Schwalier, MD
This Doctor is OpenDoctor Recommended.
|